MedTrace Logo

Evaluation of Votrient in Angiosarcoma

NCT02212015 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-03-22

Study results available
· View outcomes & findings →

Summary

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.

Conditions

  • Angiosarcoma

Interventions

DRUG

Pazopanib + Paclitaxel

pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    collaborator OTHER

  • Helios Klinikum Berlin-Buch

    collaborator OTHER

  • University Hospital Dresden

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • Hannover Medical School

    collaborator OTHER

  • Klinikum der Universitaet Muenchen, Grosshadern

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Medical University of Graz

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Peter Hohenberger, MD · Universitätsmedizin Mannheim / Heidelberg University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2019-12-31
Completion
2020-07-01

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02212015 on ClinicalTrials.gov